-
Disease Description
Crohn’s disease is an inflammatory bowel disease (IBD). Although Crohn’s is typically found in the last part of the small intestine and the first part of the large intestine, it can be found anywhere in the digestive tract, including the mouth and anus.
The main symptoms of Crohn’s are:
-Belly pain
-Diarrhea (sometimes with blood; some have it 10-20 times per day)
-Unexplained weight loss
-Mouth sores
-Bowel Blockages
-Anal tears
-Fistulas (opening between organs) Patients with Crohn’s may go long periods of time with no symptoms or have only a few, but some have the symptoms all the time.
Crohn's disease is an autoimmune disease, in which the body's immune system attacks the gastrointestinal tract, causing inflammation; it is classified as a type of inflammatory bowel disease. There has been evidence of a genetic link to Crohn's disease, putting individuals with siblings afflicted with the disease at higher risk. It is understood to have a large environmental component as evidenced by the higher number of cases in western industrialized nations. Males and females are equally affected.[1]
Prevalence
Smokers are three times more likely to develop Crohn's disease. Crohn's disease affects between 400,000 and 600,000 people in North America. Prevalence estimates for Northern Europe have ranged from 27–48 per 100,000. Crohn's disease tends to present initially in the teens and twenties, with another peak incidence in the fifties to seventies, although the disease can occur at any age.[1]
Current Treatments
There are prescription medications that can be taken to manage the symptoms, but there is no cure. At the present time, there are five basic categories of medications used in the treatment of IBD. They are:
-Aminosalicylates
-Corticosteroids
-Immunomodulators
-Antibiotics
-Biologic therapies
Medical treatment for Crohn's disease and ulcerative colitis has two main goals: achieving remission (the absence of symptoms) and, once that is accomplished, maintaining remission (prevention of flare-ups). To accomplish these goals, treatment is aimed at controlling the ongoing inflammation in the intestine—the cause of IBD symptoms.[1]
Evidence for and Proposed Mechanism for Cannabinoid Therapeutics
In a prospective clinical trial by FM Konikoff et al. it was concluded that "a short course (8 weeks) of THC-rich cannabis produced significant clinical, steroid-free benefits to 10 of 11 patients with active Crohn's disease, compared with placebo, without side effects."[2]
1. WebMD online resources
2. Konikoff FM et al. Cannabis Induces a Clinical Response in Patients With Crohn's Disease: A Prospective Placebo-Controlled Study. Clinical Gastroenterology and Hepatology. Volume 11, Issue 10, October 2013, Pages 1276–1280.e1
-
Category
Critical Ailments -
Created
Thursday, 16 March 2017 -
Group admin
CBIS
American States University
Recent GBXI News:
May 11, 2023, GBX International Group, Inc., (OTC: GBXI)
GBX International Group, Inc. (OTC:GBXI) Confirms 2023 Strong Revenue Growth Guidance Projections by Combining Each Acquired Operating Company Product Release, Expects Strong Growth Sector by Sector Through its Multiple Product Releases into North American and International Markets
April 21, 2023, GBX International Group, Inc., (OTC: GBXI)
HARVARD Award Winning Entrepreneur, Mr. Raymond C. Dabney Acquires Majority Shareholder Control of GBX International Group, Inc. (OTC: GBXI) Makes More History Bringing CSi-EDP Partner American States University (ASU) as the First Acquisition for its Aggressive Growth Plans 
The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.
Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.
We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.
Click here to review the Report:
Case No. 2:17-CV-02271-KJM-JDP
Inspire, Dream, Change
YOUR DIGITAL ERA Personal & Business Access Learning HUB
Observational Studies
Groups
-
cancer survivors
- 4
- 2310
- 0
- 0
-
COVID-19 CoronaVirus
- 16
- 2780
- 2
- 0
-
Observational Studies
- 33
- 3042
- 3
- 0
-
Cannabis Science Pharmacies
- 39
- 6042
- 3
- 0
-
Investor Relations
- 614
- 16810
- 51
- 0
Notifications
Photos
Activity Stream
I hope everyone is doing well. Raymond, Francis Cormier wrote a very detailed, informative summery over a month ago. I do not believe his 4 ever... Show more
Hi Raymond,
Per the 3rd party Cancer Drug Valuation(s) Full Report linked from this website:
On November 8, 2023; Capizate, Inc. (a 3rd party entity)...
Show more
Not sure how many... Show more 2 months ago
Cannabis Science Inc. "Shareholder Loyalty Gift Center of Excellence"
HARVARD Award Winning
CANCER Killing Success
1st HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:
*** Please click image below.
2nd HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:
*** Please click image below.
*** PLUS
(3) other Cannabis Science
REAL WORLD Successes:
Stage 4 Breast Cancer
Skin Cancer
Karposis Sarcoma
Cannabis Science CEO, Presents …
The FINAL “CBIS GIFT Shares” Issuances!
DECEMBER 1, 2022, Cheers! & HAPPY HOLIDAYS !!!
ALL GIFT Shares 1, 2, & 3 being ISSUED !!!
LAST Steps:
Please confirm Yours NOW !!!
1. CONFIRM Correct Total Share Amount(s)
2. CONFIRM Correct Name(s) on CERTIFICATE
3. CONFIRM Correct Mailing Address
ASU/CSi-EDP-ECO-System
At it's FINEST !!!
WHICH ONE ARE YOU ??
Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???
We can make this HAPPEN way FASTER Working as a TEAM !!!
WHAT Matters is how much you CARE about KILLING CANCERS ...
This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.
2023 Audit considerations NASDAQ.
Cannabis Science Inc.
Share Structure 2023
Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.
Common Stock:
Authorized:
5,000,000,000
Issued:
2,521,095,296
Class A Common Stock
Authorized:
100,000,000
Issued:
0
Class B Common Stock
Authorized:
1,500,000,000
Issued:
0
Preferred Stock
Authorized:
1,000,000
Issued:
1,000,000
Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.
You already know our Extensive LIST of GROUNDBREAKING Products.
1-Million STRONG TV Coverage, HARVARD Award Success.
TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE
*** APPLY for FREE in CONFIDENCE and Success.
Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.
EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!
"We Own everything we speak about Owning,... Show more 7 days ago
-
1Now that I'm past that NASTY Sickness phase we can... Show more 7 days ago
-
1